What We're Reading: Developing a Healthy Family Media-Use Plan
What We’re Reading, October 21, 2016: KEYNOTE-045 for pembrolizumab stopped early; new recommendations for digital media use by children; and Walgreens merger with Rite Aid pushed to 2017.
The phase 3 KEYNOTE-045 trial for pembrolizumab (Keytruda) evaluating the drug in previously treated patients with bladder cancer
Digital addiction in children may not be as bad as most presume. The American Academy of Pediatrics has released a policy statement providing guidance on age-based screen time for children. The guidance, published in the journal
- Restrict access until 18 months of age
- For 2 to 5 year-olds, limit use to an hour per day of high-quality programming
- For older children and teens, have an open conversation about screen time and regularly reevaluate limits
Walgreens and Rite Aid have pushed back the deadline to close their merger.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025